By Robb M. Stewart
BeyondSpring's shares rallied ahead of the opening bell after the biopharmaceutical company reported positive results among an Asian subset in a late-stage trial of its lung cancer treatment.
In Friday's premarket trading, the shares were 16% higher. The stock closed the previous session at $2.18, up 34% in 2025.
BeyondSpring said results from a large Asian cohort in its global Phase 3 study evaluating Plinabulin plus docetaxel in second- or third-line epidermal growth factor receptor wild-type non-small cell lung cancer showed a statistically significant improvement in overall survival compared with docetaxel alone.
The findings highlight an enhanced benefit in patients whose disease biology aligns with Plinabulin's immune-modulating and tumor vasculature-targeting mechanisms, the company said. It added that the combination also doubled two-year and three-year survival rates.
Plinabulin, a brain-penetrating, dendritic-cell maturation small molecule, demonstrated a marked reduction in docetaxel-induced grade 4 neutropenia, while maintaining a favorable tolerability profile, BeyondSpring said.
"These data from nearly 500 Asian patients further strengthen the robust global evidence supporting Plinabulin's potential to become a new standard of care for EGFR wild-type NSCLC," Lan Huang, company co-founder, chairman and chief executive, said.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
December 12, 2025 07:38 ET (12:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.